BROKERS CHOICE: INDUSTOWER, TATASTEEL, HDFCBNK, UPL, INFOEDGE, DRREDDY, CIPLA

AHMEDABAD, 8 JANUARY: અગ્રણી બ્રોકરેજ હાઉસ તથા ફંડ હાઉસ તરફથી પસંદગીના સ્ટોક્સમાં ખરીદી\ વેચાણ\ હોલ્ડ કરવા માટે ભલામણ કરવામાં આવી છે. તે રોકાણકારોના અભ્યાસ માટે અત્રે રજૂ કરીએ છીએ.

Jefferies on Bharti Airtel: Maintain Buy on Company, raise target price at Rs 2760/Sh (Positive)

Jefferies on Indus Tower: Maintain Buy on Company, raise target price at Rs 510/Sh (Positive)

HSBC on Tata Steel: Maintain Buy on Company, target price at Rs 215/Sh (Positive)

BofA on HDFC Bank: Maintain Buy on Bank, target price at Rs 1175/Sh (Positive)

BofA on ICICI Bank: Maintain Buy on Bank, target price at Rs 1750/Sh (Positive)

Jefferies on Entero: Upgrade to Buy on Company, raise target price at Rs 1320/Sh (Positive)

HSBC on UPL: Maintain Buy on Company, raise target price at Rs 925/Sh (Positive)

Citi on Car Trade: Maintain Buy on Company, raise target price at Rs 3560/Sh (Positive)

Jefferies on Telecom stocks: Jio’s IPO in 2026 expected to improve tariff discipline, lift overall sector valuations. Possible AGR relief could significantly enhance Indus Towers’ growth outlook, trigger valuation re-rating. (Positive)

CLSA on Cement Stocks: Anticipate a robust outlook in 2026 with a second consecutive year of 20%+ growth in profit pool, supported by rising demand and improved profitability (Positive)

Macquarie on Restaurant Sector: Demand remains subdued across industry, with delivery continuing to outperform dine-in, cut EPS est by 7-23% given a delayed recovery. Prefer Devyani/Sapphire > Westlife > Jubilant (Neutral)

Nomura on India’s GDP: Advance estimates confirm GDP growth moderated in H2 due to softer consumption (Neutral)

Citi on ICICI Lombard: Maintain Sell on Company, target price at Rs 1710/Sh (Neutral)

Citi on Info Edge: Maintain Sell on Company, target price at Rs 1300/Sh (Neutral)

Citi on Dr Reddy: Maintain Sell on Company, target price at Rs 990/Sh (Neutral)

Macquarie on Devyani: Maintain Outperform on Company, cut target price at Rs 160/Sh (Neutral)

Macquarie on Westlife: Maintain Outperform on Company, cut target price at Rs 600/Sh (Neutral)

Macquarie on Sapphire: Maintain Outperform on Company, cut target price at Rs 270/Sh (Neutral)

MS on Pharma sector: Cipla’s CMO Partner for Lanreotide, Pharmathen, and Gets Nine Form 483 Observations. Dr. Reddy’s Has a Moderate Regulatory Overhang Tied To OOS Handling (Negative)

Jefferies on Pharma sector: 1HCY26 likely weak for cos with Revlimid exposure like DRL, Cipla, Zydus (Negative)

Macquarie on Jubilant Food: Maintain Underperform on Company, cut target price at Rs 460/Sh (Negative)

(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)